Cathy Eng Archives
Comprehensive framework outlined for addressing early-onset colorectal cancer research
Jan. 25, 2022—New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
Eng named co-chair of NCI clinical trials steering committee
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
New drug for metastatic colorectal cancer enters phase 3 trial
Nov. 18, 2020—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
Study shows better option for treatment of inoperable anal cancer
Jun. 24, 2020—People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform
Feb. 5, 2020—Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
New Physician Spotlight: Cathy Eng
Nov. 1, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to VUMC from The University of Texas MD Anderson Cancer Center in Houston.
Colorectal cancer patients warn against dismissing early symptoms
Aug. 7, 2019—Younger patients say colorectal cancer is a disease that doesn’t follow age guidelines, so pay attention to early symptoms.
Eng named to GI cancer leadership position at VICC
Jun. 13, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
